Incorporating the Patient Voice into Attribute and Level Selection for a Preference Study: A Qualitative Study in Non-Muscle Invasive Bladder Cancer
This is the first study, to our knowledge, that provides qualitative evidence regarding patients' preference for potential future treatment options for HR-NMIBC. Findings will inform the final selection and framing of attributes and levels to be included in an upcoming benefit-risk preference study. Future research is warranted to quantify any trade-offs that patients with HR-NMIBC are willing to make regarding administration, benefit, and risk attributes.
Authors
- Anthony Eccleston
- Stephanie Chisolm (ORCID: https://orcid.org/0000-0002-6194-3163)
- Joshua Coulter (ORCID: https://orcid.org/0000-0002-1795-8536)
- Brad Mason
- Adam Gater (ORCID: https://orcid.org/0000-0001-9582-8596)
- Bethany A. Bell (ORCID: https://orcid.org/0000-0001-8225-6277)
- Julia Brinkmann (ORCID: https://orcid.org/0000-0001-8064-0101)
- Allison Thompson
- JC Cappelleri
- Pam Hallworth
- Lara Ayala-Nunes
- Raj Satkunasivam
- Jane Chang
- Brett Hauber
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Adelphi Group (United Kingdom) (GB)
- Pfizer (Germany) (DE)
- Methodist Hospital (US)
- Bladder Cancer Advocacy Network (US)
Publication Details
- Journal
- Patient
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1007/s40271-026-00804-7
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer